{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:48:27Z","timestamp":1781088507524,"version":"3.54.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T00:00:00Z","timestamp":1499904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0180430","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T13:38:29Z","timestamp":1499953109000},"page":"e0180430","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure"],"prefix":"10.1371","volume":"12","author":[{"given":"Atsushi","family":"Yaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tatemichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"S Moe","year":"2006","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","article-title":"Oral phosphate binders in patients with kidney failure","volume":"362","author":"M Tonelli","year":"2010","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1525-139X.2007.00300.x","article-title":"Renal osteodystrophy, phosphate homeostasis, and vascular calcification","volume":"20","author":"KA Hruska","year":"2007","journal-title":"Semin Dial"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000197562","article-title":"Phosphate\u2014the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review","volume":"27","author":"M Kanbay","year":"2009","journal-title":"Blood Purif"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/hy1001.096358","article-title":"Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease","volume":"38","author":"J Blacher","year":"2001","journal-title":"Hypertension"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/j.ajkd.2006.12.017","article-title":"Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients","volume":"49","author":"S Okuno","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00223-009-9278-y","article-title":"Significant association of fracture of the lumbar spine with mortality in female hemodialysis patients: a prospective observational study","volume":"85","author":"Y Maeno","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0272-6386(04)00958-8","article-title":"Increased risk of mortality associated with hip fracture in the dialysis population","volume":"44","author":"A Mittalhenkle","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"M Fukagawa","year":"2013","journal-title":"Ther Apher Dial"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1744-9987.12030","article-title":"Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients","volume":"17","author":"M Taniguchi","year":"2013","journal-title":"Ther Apher Dial"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ki.2009.60","article-title":"Oral phosphate binders","volume":"75","author":"AJ Hutchison","year":"2009","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","article-title":"Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?","volume":"88","author":"CS Shinaberger","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.clinthera.2014.09.021","article-title":"A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis","volume":"36","author":"A Bousher","year":"2014","journal-title":"Clin Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients","volume":"8","author":"RP W\u00fcthrich","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/jpet.113.204792","article-title":"PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats","volume":"346","author":"O Phan","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"515606","DOI":"10.1155\/2015\/515606","article-title":"Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure","volume":"2015","author":"O Phan","year":"2015","journal-title":"Biomed Res Int"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.ki.5000020","article-title":"Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats","volume":"69","author":"N Nagano","year":"2006","journal-title":"Kidney Int"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ki.2008.456","article-title":"A rat model of chronic kidney disease-mineral bone disorder","volume":"75","author":"SM Moe","year":"2009","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"V Shalhoub","year":"2012","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfq682","article-title":"Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure","volume":"26","author":"S Damment","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1523-1755.2003.00126.x","article-title":"Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats","volume":"64","author":"K Katsumata","year":"2003","journal-title":"Kidney Int"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000348805","article-title":"Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification","volume":"37","author":"A Iida","year":"2013","journal-title":"Am J Nephrol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12291-013-0399-8","article-title":"Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP","volume":"30","author":"BK Sarvari","year":"2015","journal-title":"Indian J Clin Biochem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ijos.2015.1","article-title":"Fibroblast growth factor 23 and bone mineralisation","volume":"7","author":"YC Guo","year":"2015","journal-title":"Int J Oral Sci"},{"issue":"Suppl 1","key":"ref25","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1097\/01.hjh.0000467394.66592.05","article-title":"1D.08: EFFECT OF PA21, A NEW IRON-BASED PHOSPHATE BINDER ON FIBROBLAST GROWTH FACTOR 23 (FGF23) AND VASCULAR CALCIFICATIONS IN UREMIC RATS","volume":"33","author":"O Phan","year":"2015","journal-title":"J Hypertens"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1517\/13543784.2014.962652","article-title":"The future of phosphate binders: a perspective on novel therapeutics","volume":"23","author":"V Cernaro","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.ajkd.2014.01.429","article-title":"Balancing nutrition and serum phosphorus in maintenance dialysis","volume":"64","author":"D Fouque","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"KA Hruska","year":"2008","journal-title":"Kidney Int"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/15.7.1014","article-title":"Arterial stiffening and vascular calcifications in end-stage renal disease","volume":"15","author":"AP Gu\u00e9rin","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/1744-9987.12068","article-title":"Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia","volume":"18","author":"T Akizawa","year":"2014","journal-title":"Ther Apher Dial"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1744-9987.2005.00294.x","article-title":"Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan","volume":"9","author":"F Koiwa","year":"2005","journal-title":"Ther Apher Dial"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1744-9987.2007.00541.x","article-title":"Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis","volume":"12","author":"T Shigematsu","year":"2008","journal-title":"Ther Apher Dial"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10157-010-0339-3","article-title":"Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients","volume":"14","author":"T Shigematsu","year":"2010","journal-title":"Clin Exp Nephrol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2165\/00003088-200847080-00004","article-title":"A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate","volume":"47","author":"F Bronner","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"GB Spasovski","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"J Floege","year":"2014","journal-title":"Kidney Int"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0180430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T06:11:48Z","timestamp":1540275108000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0180430"}},"subtitle":[],"editor":[{"given":"Mario","family":"Cozzolino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0180430","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}